home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9601.ZIP
/
M9610535.TXT
< prev
next >
Wrap
Text File
|
1996-01-30
|
2KB
|
41 lines
Document 0535
DOCN M9610535
TI HCV infection in patients with primary defects of immunoglobulin
production.
DT 9601
AU Quinti I; Pandolfi F; Paganelli R; el Salman D; Giovannetti A; Rosso R;
Oliva A; Rainaldi L; Aiuti F; Department of Allergy and Clinical
Immunology, University La; Sapienza Rome, Italy.
SO Clin Exp Immunol. 1995 Oct;102(1):11-6. Unique Identifier : AIDSLINE
MED/96003944
AB We tested for infection with hepatitis C virus (HCV) in 58 patients
affected by humoral immunodeficiencies: 43 common variable
immunodeficiency (CVI), two hyper IgM syndrome (HIM), two IgG subclass
deficiency, four ataxia-telangiectasia (AT), and seven X-linked
agammaglobulinaemia (XLA). While the assessment of serum specific HCV
antibodies in some of these patients was not informative because of the
impairment in specific antibody production, the reverse transcriptase
polymerase chain reaction (RT-PCR) assay used to detect serum HCV RNA
was a useful method for diagnosing infection. We found that 38% of late
onset hypogammaglobulinaemic patients (CVI, HIM or IgG subclass
deficiency) had evidence of HCV infection. HCV infection was not
detectable in patients with XLA or AT. The majority of our patients had
persistent viraemia, and those who underwent liver biopsy showed
histological findings of chronic hepatitis. Moreover, we could
demonstrate in vitro that eight of 18 HCV-infected patients were
actively producing anti-HCV antibodies, despite their impaired antibody
production. The high rate of HCV infection in hypogammaglobulinaemic
patients could be related to several nosocomial routes of transmission,
including intravenous immune globulin administration. Despite the
persistent viremia only two patients had cirrhosis and none had
hepatocarcinoma.
DE Adolescence Adult Agammaglobulinemia/*COMPLICATIONS Child Female
Hepatitis C/*ETIOLOGY/IMMUNOLOGY Hepatitis C Antibodies/BLOOD Human
Immunoglobulins/BIOSYNTHESIS Immunoglobulins, Intravenous/ADVERSE
EFFECTS Lymphocyte Transformation Male Middle Age RNA, Viral/BLOOD
Support, Non-U.S. Gov't JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).